Moosa Mohammadi

This inventor holds 22 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: New York University, Pfizer Corporation, Sugen Incorporated. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Moosa Mohammadi. Retrieved from https://idiyas.com/inventor/moosa-mohammadi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 3)

% Patents Active = 90.9

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.2

ph-index = 12

Forward Citations = 403(Granted Patents)

Location History:

New York, NY (US) (1999 - 2007)
Scarsdale, NY (US) (2006 - 2020)

Company Filing History:

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12227777 - Soluble alpha-Klotho proteins, protein fragments, and uses thereof (2025-02-18),

2. 10703788 - Chimeric fibroblast growth factor 21 proteins and methods of use (2020-07-07),

3. 10633424 - Chimeric fibroblast growth factor 19 proteins and methods of use (2020-04-28),

4. 10464979 - FGF23 c-tail fusion proteins (2019-11-05),

5. 10364278 - Chimeric fibroblast growth factor 23 proteins and methods of use (2019-07-30),

6. 10174090 - FGF21 protein with enhanced binding affinity for β-Klotho for the treatment of type II diabetes, obesity, and related metabolic disorders (2019-01-08),

7. 9926356 - Chimeric fibroblast growth factor 19 proteins and methods of use (2018-03-27),

8. 9926355 - Chimeric fibroblast growth factor 21 proteins and methods of use (2018-03-27),

9. 9907830 - Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of chronic kidney disease and symptoms and/or complications thereof (2018-03-06),

10. 9657075 - Chimeric fibroblast growth factor 23 proteins and methods of use (2017-05-23),

11. 9550820 - Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use (2017-01-24),

12. 9475856 - Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders (2016-10-25),

13. 9474785 - Chimeric fibroblast growth factor 19 proteins and methods of use (2016-10-25),

14. 9464126 - Chimeric fibroblast growth factor 21 proteins and methods of use (2016-10-11),

15. 9272017 - Pharmaceutical compositions including a portion of the C-terminus of FGF23 (2016-03-01),

Title: The Innovative Journey of Inventor Moosa Mohammadi

Introduction: Moosa Mohammadi, a talented inventor based in Scarsdale, NY, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Moosa Mohammadi's latest patents include cutting-edge technologies in the field of artificial intelligence and renewable energy, showcasing his commitment to creating solutions for a sustainable future.

Career Highlights: With a background in engineering and a passion for innovation, Moosa Mohammadi has a successful career marked by numerous patents that have revolutionized industries such as healthcare, transportation, and communication.

Collaborations: Throughout his career, Moosa Mohammadi has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work in multidisciplinary teams has led to the development of groundbreaking technologies.

Conclusion: Moosa Mohammadi's dedication to innovation and his relentless pursuit of technological advancement make him a standout inventor in the field. His contributions continue to shape the future of various industries, leaving a lasting impact on society.

Profile summary based on public USPTO records.